DUOPHARMA BIOTECH BERHAD (formerly known as CCM Duopharma Biotech Berhad) INVESTORS RELATION BRIEFING 5 SEPTEMBER 2019 1
Disclaimer This presentation may contain forward-looking statements by Duopharma Biotech Berhad that reflect management’s current expectations, beliefs, intentions or strategies regarding the future and assumptions in light of currently available information. These statements are based on various assumptions and made subject to a number of risks, uncertainties and contingencies. Actual results, performance or achievements may differ materially and significantly from those discussed in the forward-looking statements. Such statements are not and should not be construed as a representation, warranty or undertaking as to the future performance or achievements of Duopharma Biotech Berhad and Duopharma Biotech Berhad assumes no obligation or responsibility to update any such statements. No representation or warranty (either express or implied) is given by or on behalf of Duopharma Biotech Berhad or its related corporations (including without limitation, their respective shareholders, directors, officers, employees, agents, partners, associates and advisers) (collectively, the " Parties ") as to the quality, accuracy, reliability or completeness of the information contained in this presentation (collectively, the " Information "), or that reasonable care has been taken in compiling or preparing the Information. None of the Parties shall be liable or responsible for any budget, forecast or forward-looking statements or other projections of any nature or any opinion which may have been expressed in the Information. The Information is and shall remain the exclusive property of Duopharma Biotech Berhad and nothing herein shall give, or shall be construed as giving, to any recipient(s) or party any right, title, ownership, interest, licence or any other right whatsoever in or to the Information herein. The recipient(s) acknowledges and agrees that this presentation and the Information are confidential and shall be held in complete confidence by the recipient(s). No part of this presentation is intended to or construed as an offer, recommendation or invitation to subscribe for or purchase any securities in Duopharma Biotech Berhad . 2
Journey of Jo f Duopharma Biotech Berhad FY 2007 FY 2015 28 DEC 2017 25 FEB 2019 FY 2005 FY 2006 Chemical CCMB CCM Company of underwent a Duopharma CCMD has Malaysia CCM Pharma corporate de-merged Duopharma changed its Berhad Sdn Bhd restructuring. from CCMB. was rebranded name to (“CCMB”) acquired the to CCM Duopharma Therefore, acquired assets and Duopharma Biotech All of its CCMD became Duopharma brands of Biotech Berhad pharmaceutical an Biotech Berhad, Malayan (“CCMD”). (“ Duopharma subsidiaries independent the listed entity Pharma. Biotech”). were placed public listed , incorporated under CCMD. company. in 2000. 3
Implications of Im f the De-merger We are REQUIRED to We are REQUIRED We are UNABLE to We are REQUIRED to change the company to have our own carry CCM brand / establish our own vision name and its corporate identity name and mission subsidiaries 4
Logo Description Colour of the logo ▪ Logo is rendered in bold red, the colour of passion Letter ‘D’ and ‘B’ inside the hexagon ▪ D and B stand for ‘ Duopharma ’ and ‘Biotech ’ Shape ▪ Modern ▪ Symbolises innovation across every aspect of the business ▪ Six sides represent the company’s six core values Name of Duopharma at the bottom ▪ Expressed in a font that perfectly balances rounded shapes ▪ “Duo” represents the company’s two main businesses – prescription medicines and consumer healthcare products 5
New Vision, Mission and Tagline New VISION Providing smarter solutions for a healthier life New MISSION A leading Healthcare Group providing quality and innovative solutions New TAGLINE Smarter Solutions. Healthier Life. 6
Change of f Name of Company Old Company Name New Company Name Status Duopharma Marketing Effective from 26 December CCM Pharmaceuticals Sdn. Bhd. 2018 Sdn. Bhd. Duopharma Manufacturing Effective from 26 December Upha Pharmaceutical (Bangi) Sdn. Bhd. 2018 Manufacturing (M) Sdn. Bhd. Duopharma Innovation Effective from 26 December Sdn. Bhd. 2018 Innovax Sdn. Bhd. Duopharma HAPI Sdn. Bhd. Effective from 26 December CCM Biopharma Sdn. Bhd. 2018 Duopharma Effective from 26 December Manufacturing 2018 CCM Pharma Sdn. Bhd. (Glenmarie) Sdn. Bhd. 7
Change of f Name of Company Old Company Name New Company Name Status Duopharma (M) Sendirian Duopharma (M) Sendirian No change to company Berhad Berhad name Sentosa Pharmacy Sdn. Sentosa Pharmacy Sdn. No change to company Bhd. Bhd. name Unique Pharmacy (Penang) Unique Pharmacy No change to company Sdn. Bhd. (Penang) name Sdn. Bhd. Negeri Pharmacy Sdn. Bhd. Negeri Pharmacy Sdn. No change to company Bhd. name 8
Change of f Name of Company Old Company Name New Company Name Status CCM Pharmaceuticals (S) Duopharma (Singapore) Effective from 4 January Pte. Ltd. Pte. Ltd. 2019 CCM International DB (Philippines), Inc. Effective from 15 February (Philippines), Inc. 2019 CCM Duopharma Biotech Duopharma Biotech Effective from 25 February Berhad Berhad 2019 Unique Pharmacy (Ipoh) Duopharma Consumer Effective from 21 June 2019 Sdn. Bhd. Healthcare Sdn Bhd 9
Corporate Structure 10
Shareholding Stru ructure Others, 41.5% PNB, 45.4% DPHARMA (Stock Code – 7148) Amanahraya Trustees Market capitalization on 29.08.2019 Berhad,ASB, = RM 965.8 mil EPF, 7.3% 5.8% Share price = RM 1.42 Note: Shareholding as at 31 July 2019 11
Board of f Directors Senior Independent Non- Non-Independent & Non- Executive Director Executive Chairman Tan Sri Datin Paduka Siti Dato' Mohamad Kamarudin Sa'diah Binti Sh Bakir Executive Director bin Hassan Group Managing Director Encik Leonard Ariff bin Independent Non- Abdul Shatar Independent Non- Executive Director Executive Director Puan Zaiton binti Encik Razalee bin Amin Independent Non- Jamaluddin Executive Director Datuk Nik Moustpha bin Independent and Non- Non-Independent and Hj Nik Hassan Executive Director Non-Executive Dato' Eisah Binti A. Datuk Mohd Radzif Bin Rahman Mohd Yunus 12
Board of f Directors STRUCTURE Board of Directors Nomination and Risk Management and Audit and Integrity Remuneration Halal Committee Sustainability Committee Committee Committee Chairman: Datuk Nik Moustpha bin Hj Nik Chairman: Encik Razalee Chairman: Dato’ Chairman: Datuk Mohd Hassan bin Amin Mohamad Kamarudin bin Radzif bin Mohd Yunus Hassan 13
Group Management Committee Leonard Ariff Abdul Shatar Group Managing Director Rama Sockalingam Nagappan Anita binti Esa Head, Group Internal Head, Group Risk Management Audit & Integrity Wan Amir-Jeffery Wan Krisnakumara-Reddi Chek Wu Kong Ng Su Yee Billy Urudra Ibrahim Hussin Salleh Abdul Majid Chief Manufacturing Officer Chief Financial Officer Chief Technical Officer Chief Commercial Officer Chief Legal Officer Chief Operating Officer 14
Financial Highlights RM’ million RM’million 70 600 (in YTD June 2016 2017 2018 RM'million) 2019 60 500 50 Non-current 400 295.3 348.6 469.0 479.2 assets 40 300 Current 30 366.2 356.6 367.3 431.5 assets 200 20 Equities 454.5 479.9 481.0 503.7 100 10 Liabilities 206.9 225.4 355.3 407.0 0 0 YTD June 2016 2017 2018 2019 Gearing 0.25x 0.27x 0.51x 0.52x PBT 31.5 51.8 59.7 37.1 PAT 26.8 42.5 47.6 28.4 Return on 5.6% Revenue 312.9 468.0 498.7 295.9 5.9% 8.8% 9.9% Equity (H1 2019) PBT PAT Revenue Internal Restructuring completed on 24 May 2018 enables the Group to be more nimble in securing potential business opportunities and more tax efficient. 15
Fin inancial Hig ighlights – Segmental Sale les Export Export Export 7% 8% 8% Local (Government) Local Local Local Local (Government) (Government) Local (Private) 52% (Private) 49% 50% 42% (Private) 43% 41% FY 2018 Revenue : YTD June 2019 Revenue : FY 2017 Revenue : RM 498.72 mil RM 295.85 mil RM 467.99 mil Note: Duopharma Biotech’s top export markets for first half of FY2019 (% based on export revenue) : 1.Singapore – 29.1% (RM6.4mil) 2.Middle East – 18.1% (RM4.0mil) 3.Philippines – 17.6% (RM3.9mil) 16
Recommend
More recommend
